# FDA-approved drug may help immunotherapy break through rare liver cancer’s defenses

> Researchers at Cornell University and the University of Washington have identified a potential way to help immunotherapy reach a rare liver cancer that often affects young people. Their study in Gastroenterology suggests that the FDA-approved drug AMD3100 can help release immune cells...

Canonical URL: https://www.argo.net/fda-approved-drug-may-help-immunotherapy-break-through-rare-liver-cancers-defenses/
Byline: Cornell University
Published: 2026-07-10T04:25:09+00:00
Categories: Health, News

![Scrabble tiles spell out 'Liver Cancer' on a dark blue background, symbolizing awareness](https://www.argo.net/wp-content/uploads/2026/06/liver_cancer_cells.jpg)

Researchers at [Cornell University](https://news.cornell.edu/stories/2026/02/drug-lifts-barrier-immunotherapy-fight-rare-liver-cancer) and the University of Washington have identified a potential way to help immunotherapy reach a rare liver cancer that often affects young people. Their study in Gastroenterology suggests that the FDA-approved drug AMD3100 can help release immune cells that become stranded inside fibrolamellar carcinoma tumors.

The finding matters because **fibrolamellar carcinoma** has offered doctors few good treatment options. This cancer is rare, aggressive and often diagnosed after it has already spread. Immunotherapy has transformed care for some cancers, yet this disease has remained stubbornly resistant.

The new work points to a physical and chemical barrier inside the tumor. Instead of reaching cancer cells, T cells are drawn toward fibrous bands that run through the tumor. Blocking that signal allowed the immune cells to move into the tumor core in laboratory tests using patient tissue.

## A rare liver cancer that locks out immune cells

Fibrolamellar carcinoma accounts for only a small fraction of liver cancer cases. It mainly affects children and young adults, often in people without the liver scarring usually linked to more common liver cancers. That unusual profile has made the disease especially difficult to study.

The Cornell and University of Washington team focused on why **immune checkpoint inhibition** has had limited success against this tumor type. Checkpoint inhibitors are designed to free T cells so they can attack cancer. In fibrolamellar carcinoma, many of those T cells appear to be kept away from the cancer cells they need to reach.

Researchers describe this problem as **T-cell exclusion**. The immune cells are present, yet they collect in the wrong areas of the tumor. Praveen Sethupathy of Cornell said the findings show that "this T-cell exclusion phenomenon is an important one to tackle in fibrolamellar carcinoma."

That distinction is clinically important. If T cells can't enter the tumor core, then activating them may have limited effect. The study suggests that improving access could make immunotherapy more effective in this rare cancer.

## The fibrous bands that trap T cells

The name fibrolamellar carcinoma comes from the dense fibrous bands visible inside the tumors. These bands have long been a defining feature of the disease. Their role in cancer progression has remained difficult to pin down.

Andreas Stephanou, a Cornell graduate student and co-first author, described that uncertainty with the phrase, "Despite all of the recent advances in the study of this cancer." The team's analysis now links those bands to an immune escape strategy.

The researchers found that the bands are produced by altered **stellate cells**. These cells normally exist in the liver, but the tumor changes their behavior. Once altered, they release fibrous proteins that build the thick bands throughout the tumor.

Those same altered cells also appear to send directional signals to nearby T cells. The signals pull immune cells toward the fibrous regions. As a result, the T cells gather in the stroma and remain separated from cancer cells.

This helps explain how the tumor's structure can shape the immune response. The fibrous bands are more than a visual hallmark. They help create a neighborhood where immune cells are misdirected.

## Single-cell tools reveal the tumor's signals

To map what was happening inside these tumors, the team used **single-nucleus transcriptomics**. This method lets scientists examine gene activity in individual cell nuclei. It gives a detailed view of which cells are present and what signals they may be sending.

That approach helped reveal interactions between tumor-associated stromal cells and immune cells. In particular, the researchers identified signaling involving CXCL12-producing myofibroblasts and CXCR4-bearing lymphocytes. In plain terms, one group of cells was sending a chemical cue and immune cells were equipped to follow it.

The receptor **CXCR4** became a key target. If the signal through this receptor was helping lure T cells away from cancer cells, then blocking the receptor might change immune cell movement. Sethupathy framed the next step simply, asking, "what if we were to block this signaling in T cells with a compound?"

The study also fits a broader challenge in cancer immunology. Some tumors contain immune cells that look ready to fight, yet those cells are either exhausted or stuck in unhelpful locations. Fibrolamellar carcinoma appears to use both problems.

By combining spatial information with single-cell gene data, the researchers built a clearer picture of the tumor microenvironment. The result is a mechanism that can be tested. That makes the finding more actionable than a descriptive map alone.

## AMD3100 helps immune cells reach the tumor core

The compound tested by the team was **AMD3100**. It is already approved by the U.S. Food and Drug Administration for another medical use. In this study, researchers tested whether it could block the CXCR4 signal that helps keep T cells trapped in the tumor stroma.

The **University of Washington** group used **patient tumor slices** to test the idea. These slices preserve important parts of the tumor's architecture, including the cancer cells, immune cells and surrounding fibrous tissue. That made them useful for watching how T cells responded when the signal was blocked.

After AMD3100 treatment, T cells moved toward the center of the tumor. This result suggested that the drug could help overcome the exclusion pattern seen in fibrolamellar carcinoma. The effect was observed in tissue experiments, so patient trials will be needed to learn whether the same strategy works safely in people.

The team also tested AMD3100 with checkpoint blockade. When paired with **PD-1 blockade**, T-cell activation increased further. The combination also produced a significant increase in tumor cell death in the experimental setting.

That combination is central to the study's promise. AMD3100 may help immune cells arrive where they are needed, while checkpoint inhibition may help those cells attack once they get there. Together, the drugs target two separate barriers.

## A possible path toward clinical trials

The next step is clinical testing. The researchers are seeking liver cancer specialists interested in evaluating the treatment approach in patients with fibrolamellar carcinoma. Because the disease is rare, building such trials can require collaboration across cancer centers.

Sethupathy noted one practical advantage, saying, "AMD3100 is already FDA-approved." A drug with an existing approval can sometimes move into trials more quickly than a brand-new compound. Safety, dosing and treatment schedules still have to be studied for this specific cancer strategy.

The work remains early-stage. The strongest evidence comes from tumor tissue studies and detailed molecular analysis. It offers a rationale for human trials rather than proof of clinical benefit.

Even so, the study gives researchers a clearer target. Instead of treating immune resistance as a single problem, the findings divide it into distinct steps. T cells need access to the tumor core and they need enough activation to kill cancer cells once they arrive.

For patients with a rare cancer that has resisted many treatment approaches, that clarity could matter. The discovery suggests that the tumor's own fibrous architecture may be rewired into a therapeutic opening.